Hong Kong and Macau Suspend Pfizer-BioNTech COVID-19 Vaccination over Alleged Flawed Vials

Hong Kong and Macau authorities have suspended the vaccination roll-out of BioNTech’s COVID-19 vaccine as a defect was found in the first batch of doses.

Governments of the two countries said in statements on Wednesday that they had received a letter from BioNTech and its Chinese partner, Fosun Pharma, indicating an issue with the seal on individual vials in batch number 210102.

Despite the Fosun and BioNTech did not found “any reason to believe that product safety is at risk,” the Hong Kong government still suspends vaccinations involving batch 210102.

These are preventive measures to continuously ensure the safety of the vaccination program,” said in a statement.

According to government figures, as of Tuesday, 150,200 people in Hong Kong had received their first dose of the BioNTech vaccine.

Hong Kong is expected to receive doses of the AstraZeneca vaccine.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.